CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade TG Therapeutics, Inc. - TGTX CFD

32.17
4.25%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 30.86
Open 30.6
1-Year Change 62.94%
Day's Range 30.6 - 32.48
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 32.17 1.77 5.82% 30.40 32.54 30.40
Dec 19, 2024 30.86 -0.42 -1.34% 31.28 31.55 30.37
Dec 18, 2024 31.01 -2.52 -7.52% 33.53 33.54 30.36
Dec 17, 2024 33.50 -0.71 -2.08% 34.21 34.95 33.25
Dec 16, 2024 34.33 2.33 7.28% 32.00 34.93 31.95
Dec 13, 2024 31.99 1.33 4.34% 30.66 32.11 30.35
Dec 12, 2024 30.64 -1.01 -3.19% 31.65 32.13 30.40
Dec 11, 2024 31.62 -0.29 -0.91% 31.91 32.22 30.99
Dec 10, 2024 31.61 -1.29 -3.92% 32.90 33.40 31.47
Dec 9, 2024 32.80 -0.86 -2.55% 33.66 33.93 32.66
Dec 6, 2024 33.86 0.12 0.36% 33.74 34.63 33.58
Dec 5, 2024 33.61 0.01 0.03% 33.60 34.57 33.51
Dec 4, 2024 33.80 0.55 1.65% 33.25 34.19 33.10
Dec 3, 2024 33.32 -1.55 -4.45% 34.87 35.35 33.12
Dec 2, 2024 35.03 0.48 1.39% 34.55 35.14 33.70
Nov 29, 2024 34.68 -0.45 -1.28% 35.13 35.62 34.66
Nov 27, 2024 34.94 0.41 1.19% 34.53 34.98 33.60
Nov 26, 2024 34.19 0.17 0.50% 34.02 34.57 33.56
Nov 25, 2024 34.53 -1.29 -3.60% 35.82 36.67 34.46
Nov 22, 2024 35.00 0.53 1.54% 34.47 35.24 33.67

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

TG Therapeutics, Inc. Company profile

About TG Therapeutics Inc

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, TG Therapeutics Inc revenues increased from $152K to $6.7M. Net loss increased 25% to $348.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other general and administrative increase from $41.5M to $90.9M (expense), Other research and development increase of 31% to $198.5M (expense).

Equity composition

Common Stock $.05 Par, 04/12, 500M auth., 5,058,834 issd. Insiders & stakeholders own 39.30%. Preferred Stock $.001 Par, 1.5M auth. 03/08 Company delisted from AMEX to OTC Bulletin Board. 07/11, 1-for-50 reverse stock split. 04/12, 1-for-56.25 Reverse split.

Industry: Biotechnology & Medical Research (NEC)

3020 Carrington Mill Blvd., Suite 475
MORRISVILLE
NORTH CAROLINA 27560-5435
US

People also watch

Gold

2,620.17 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0151%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,361.10 Price
+0.370% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

ETH/USD

3,236.35 Price
-2.050% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

94,299.35 Price
-2.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading